Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net (loss) income	$ (89,577)	$ 6,837
Adjustments to reconcile net (loss) income to net cash used in operating activities
Intangible asset impairment charges	69,900	0
Stock-based compensation	17,671	8,891
Amortization of intangible assets	8,236	5,340
Depreciation	5,056	3,035
Non-cash lease expense	1,025	1,795
Loss on disposal of property and equipment, net	54	0
(Gain) loss on disposal of assets held for rent, net	369	333
Change in fair value of warrant liability	(0)	121
Change in fair value of equity investments	(697)	0
Change in fair value of contingent consideration	(3,348)	1,086
Deferred income tax benefit	(4,937)	(17,540)
Gain on acquisition of Sexton Biotechnologies, Inc.	0	(6,451)
Other	302	504
Change in operating assets and liabilities, net of effects of acquisitions
Accounts receivable, trade, net	(9,438)	(7,140)
Inventories	(5,403)	(1,237)
Prepaid expenses and other assets	(1,356)	1,769
Accounts payable	(3,615)	1,368
Accrued expenses and other current liabilities	444	(2,530)
Warranty liability	(1,031)	0
Net cash used in operating activities	(16,345)	(3,819)
Cash flows from investing activities
Cash acquired in acquisition of Global Cooling, Inc.	0	1,559
Maturities of available-for-sale securities	750
Proceeds from sale of equipment	0	22
Purchases of assets held for rent	(2,269)	(5,412)
Purchases of property and equipment	(5,937)	(6,819)
Investment in available-for-sale securities	(35,767)	0
Net cash used in investing activities	(43,223)	(10,650)
Cash flows from financing activities
Proceeds from line of credit	0	26,450
Payments on line of credit	0	(28,657)
Proceeds from exercise of common stock options	307	1,017
Fees paid related to issuance of common stock	(130)	(145)
Other	(302)	(280)
Net cash provided by (used in) financing activities	16,941	(673)
Net decrease in cash, cash equivalents, and restricted cash	(42,627)	(15,142)
Cash, cash equivalents, and restricted cash – beginning of period	69,870	90,456
Effects of currency translation on cash, cash equivalents, and restricted cash	(176)	(163)
Cash, cash equivalents, and restricted cash – end of period	27,067	75,151
Non-cash investing and financing activities
Purchase of property and equipment not yet paid	1,661	305
Cashless issuance of SciSafe earnout shares	817	0
Equipment acquired under operating leases	243	6,971
Unrealized gains and losses on available-for-sale securities	75	0
Stock issued as consideration to acquire Global Cooling, Inc. and Sexton Biotechnologies, Inc.	0	264,718
Cashless exercise of warrants reclassified from warrant liability to common stock	0	2,901
Equipment acquired under finance leases	0	440
Cash interest paid	230	0
The 2022 Term Loan [Member]
Cash flows from financing activities
Proceeds from loans	20,000	0
Payments on loans	(1,750)	0
Equipment Loans [Member]
Cash flows from financing activities
Proceeds from loans	0	1,640
Payments on loans	(370)	0
Financed Insurance Premium [Member]
Cash flows from financing activities
Payments on financed insurance premium	$ (814)	$ (698)